Clinical Rheumatology

, Volume 25, Issue 4, pp 482–486 | Cite as

CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications—results of a retrospective analysis of 117 cases

  • Ina Kötter
  • Ilhan Günaydin
  • Marion Batra
  • Reinhard Vonthein
  • Nicole Stübiger
  • Gerhard Fierlbeck
  • Arthur Melms
Original Article


The aim of this study was to evaluate the incidence of neurological manifestations of Behçet's disease (BD) in patients on cyclosporin A (CSA) compared with those on other medications. The records of 117 patients with BD who visited our hospital between 1990 and 2003 were reviewed with respect to symptoms and medication. All episodes of constant therapy prior to central nervous system (CNS) involvement were counted, and then the associations were analysed by the exact Fisher–Freeman–Halton test and adjusted for multiple tests by the Bonferroni–Holm method. We observed ten new cases of CNS manifestations in our patients with BD being regularly seen and treated in our tertiary care centre. The overall prevalence of neuro-BD in our patient group was 8.5%. In a retrospective analysis, the incidence of new-onset neurological disease (neuro-BD) in all patients with BD who regularly visited our hospital was significantly higher in patients on CSA than in those on other medications (6 of 21 vs 0 of 175 episodes, P<0.0001). This contrasts the obvious efficacy of CSA on extracerebral manifestations of BD, such as severe ocular disease, mucocutaneous lesions or arthritis. CSA exerts differential efficacy on various manifestations of BD. It is very effective for severe ocular and other moderate to severe manifestations of BD, but its efficacy for the prevention of neuro-BD seems to be inferior to that of other medications used in BD, such as azathioprine or interferon-α. The reasons for this are unclear, but the potential toxic effects of CSA on the CNS may be a predisposing factor for CNS vasculitis in BD.


Behçet's disease CNS manifestations CSA 



We thank Prof. Hasan Yazici for his critical review of the manuscript, and Prof. CA Mueller for the human leukocyte antigen (HLA) analyses.


  1. 1.
    International Study Group for Behcet's Disease (1990) Criteria for diagnosis of Behcet's disease. Lancet 335:1078–1080Google Scholar
  2. 2.
    Kidd D, Steuer A, Denman AM, Rudge P (1999) Neurological complications in Behcet's syndrome. Brain 122(Pt 11):2183–2194CrossRefPubMedGoogle Scholar
  3. 3.
    Akman-Demir G, Serdaroglu P, Tasci B (1999) Clinical patterns of neurological involvement in Behcet's disease: evaluation of 200 patients. The Neuro-Behcet Study Group. Brain 122(Pt 11):2171–2182CrossRefPubMedGoogle Scholar
  4. 4.
    Siva A, Kantarci OH, Saip S, et al (2001) Behcet's disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 248:95–103CrossRefPubMedGoogle Scholar
  5. 5.
    Dilsen N, Konice M, Aral O (1985) Our diagnostic criteria of Behcet's disease—an overview. In: Lehner T, Barnes CG (eds) Recent advances in Behçet's disease. Royal Society of Medicine Services, London, pp 177–180Google Scholar
  6. 6.
    Krause I, Rosen Y, Kaplan I, et al (1999) Recurrent aphthous stomatitis in Behcet's disease: clinical features and correlation with systemic disease expression and severity. J Oral Pathol Med 28:193–196PubMedCrossRefGoogle Scholar
  7. 7.
    Kotter I, Vonthein R, Muller CA, Gunaydin I, Zierhut M, Stubiger N (2004) Behcet's disease in patients of German and Turkish origin living in Germany: a comparative analysis. J Rheumatol 31:133–139PubMedGoogle Scholar
  8. 8.
    Saenz A, Ausejo M, Shea B, Wells G, Welch V, Tugwell P (2000) Pharmacotherapy for Behcet's syndrome. Cochrane Database Syst Rev 2:CD001084Google Scholar
  9. 9.
    Hinchey J, Chaves C, Appignani B, et al (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334:494–500CrossRefPubMedGoogle Scholar
  10. 10.
    Gijtenbeek JMM, van den Bent MJ, Vecht CJ (1999) Cyclosporine neurotoxicity: a review. J Neurol 246:339–346CrossRefPubMedGoogle Scholar
  11. 11.
    Filley CM, Kleinschmidt-DeMasters BK (2001) Toxic leukoencephalopathy. N Engl J Med 345:425–432CrossRefPubMedGoogle Scholar
  12. 12.
    Lee SH, Yoon PH, Park SJ, Kim DI (2001) MRI findings in neuro-Behçet's disease. Clin Radiol 56:485–494CrossRefPubMedGoogle Scholar
  13. 13.
    Kato Y, Numaga J, Kato S, Kaburaki T, Kawashima H, Fujino Y (2001) Central nervous system symptoms in a population of Behcet's disease patients with refractory uveitis treated with cyclosporine A. Clin Experiment Ophthalmol 29:335–336CrossRefPubMedGoogle Scholar
  14. 14.
    Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H (1999) Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy. Ophthalmology 106:586–589CrossRefPubMedGoogle Scholar
  15. 15.
    Meusser S, Eger G, Anders M, Burkhardt H, Kalden JR (1997) Manifestation of neuro-Behcet disease in cyclosporin A therapy. Z Rheumatol 56:31–39CrossRefPubMedGoogle Scholar
  16. 16.
    Lannuzel A, Lamaury I, Charpentier D, Caparros-Lefebvre D (2002) Neurological manifestations of Behcet's disease in a Caribbean population: clinical and imaging findings. J Neurol 249:410–418CrossRefPubMedGoogle Scholar
  17. 17.
    Serdaroglu P (1998) Behcet's disease and the nervous system. J Neurol 245:197–205CrossRefPubMedGoogle Scholar
  18. 18.
    McLean BN, Miller D, Thompson EJ (1995) Oligoclonal banding of IgG in CSF, blood–brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behcet's disease involving the nervous system. J Neurol Neurosurg Psychiatry 58:548–554PubMedGoogle Scholar
  19. 19.
    Motomura S, Tabira T, Kuroiwa Y (1980) A clinical comparative study of multiple sclerosis and neuro-Behcet's syndrome. J Neurol Neurosurg Psychiatry 43:210–213PubMedCrossRefGoogle Scholar
  20. 20.
    Krause I, Leibovici L, Guedj D, Molad Y, Uziel Y, Weinberger A (1999) Disease patterns of patients with Behcet's disease demonstrated by factor analysis. Clin Exp Rheumatol 17:347–350PubMedGoogle Scholar
  21. 21.
    Yurdakul S, Mat C, Tuzun Y, et al (2001) A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 44:2686–2692CrossRefPubMedGoogle Scholar
  22. 22.
    Hamuryudan V, Mat C, Saip S, et al (1998) Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:443–450PubMedGoogle Scholar
  23. 23.
    Kotter I, Vonthein R, Zierhut M, et al (2004) Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial. Semin Arthritis Rheum 33:311–319CrossRefPubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2005

Authors and Affiliations

  • Ina Kötter
    • 1
  • Ilhan Günaydin
    • 1
  • Marion Batra
    • 2
  • Reinhard Vonthein
    • 3
  • Nicole Stübiger
    • 4
  • Gerhard Fierlbeck
    • 5
  • Arthur Melms
    • 6
  1. 1.Department of Internal Medicine II (Hematology/Oncology/Immunology/Rheumatology)University HospitalTübingenGermany
  2. 2.Department of Neuro-RadiologyUniversity HospitalTübingenGermany
  3. 3.Department of Medical BiometryUniversity HospitalTübingenGermany
  4. 4.Department of OphthalmologyUniversity HospitalTübingenGermany
  5. 5.Department of DermatologyUniversity HospitalTübingenGermany
  6. 6.Department of NeurologyUniversity HospitalTübingenGermany

Personalised recommendations